News & Press Releases

INTEGRITY APPLICATIONS COMMON STOCK IS PUBLICLY QUOTED ON THE OTC BULLETIN BOARD UNDER THE SYMBOL “IGAP”

April 10th, 2013

INTEGRITY APPLICATIONS COMMON STOCK IS PUBLICLY QUOTED ON THE OTC BULLETIN BOARD UNDER THE SYMBOL “IGAP”   Raises approximately $6.3 million to advance the development and commercialization of GlucoTrack® for the non-invasive measurement of blood glucose   ASHKELON, Israel (April 9, 2013) – Integrity Applications, Inc. (OTCQB:IGAP), developer of the GlucoTrack DF-F non-invasive blood glucose […]

Read More Download

Archive

Sign up to our newsletter
To receive occasional news updates

LinkedIn Facebook Twitter

GlucoTrack® intended use: GlucoTrack® Model DF-F is a non-invasive intermittent glucose monitoring device for home-use. GlucoTrack® model DF-F is intended for adults 18 years and older with type 2 diabetes or pre-diabetes.

Medications intake and/or treatment decisions should not be based solely on GlucoTrack® model DF-F measurements. GlucoTrack® Model DF-F is a glucose monitoring device and should not be used for diagnosis purposes.

© 2022 Integrity Applications. All Rights Reserved.